David Cella1, Jennifer L Beaumont, Kimberly A Webster, Jin-Shei Lai, Linda Elting. 1. Center on Outcomes, Research and Education, Evanston Northwestern Healthcare, Feinberg School of Medicine, Northwestern University, 1001 University Place, Suite 100, Evanston, IL 60201, USA. d-cella@northwestern.edu
Abstract
PURPOSE: The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General. MATERIALS AND METHODS: An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenic patients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancer patients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks. RESULTS: All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients. CONCLUSION: The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients' lives. It can distinguish cancer patients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.
PURPOSE: The specific concerns of people with low platelet counts (thrombocytopenia) have not been characterized well in the literature and as a result proper measurement of patient-reported concerns is lacking. We report on the development and validation of questions specifically targeted to patients with thrombocytopenia that can be added to the more general concerns in the Functional Assessment of Cancer Therapy-General. MATERIALS AND METHODS: An 18-item FACT-Thrombocytopenia Subscale (ThS) was rated and evaluated by thrombocytopenicpatients at baseline during a validation study of 40 thrombocytopenic and 43 nonthrombocytopenic cancerpatients. To evaluate responsiveness, patients completed a battery of self-report measures including the FACT-Th and were followed up for change in platelet count over 2 weeks. RESULTS: All subscales and aggregated scores showed high internal consistency at initial assessment and at retesting. Convergent and divergent validity were demonstrated by predicted relationships between FACT-Th subscales and mood, mental and physical component scores of the SF-36, and social desirability. The ThS differentiated patients with low platelets from those with normal platelet counts and good performance from poor performance status patients. CONCLUSION: The FACT-Th is a reliable and valid measure for assessing the impact of thrombocytopenia on patients' lives. It can distinguish cancerpatients with and without thrombocytopenia and is responsive to increase in platelet count over time. The FACT-Th may therefore prove useful as a measure of self-reported symptoms and concerns related to thrombocytopenia in clinical trials evaluating new pharmacologic agents and/or platelet transfusion practice.
Authors: C A Schiffer; K C Anderson; C L Bennett; S Bernstein; L S Elting; M Goldsmith; M Goldstein; H Hume; J J McCullough; R E McIntyre; B L Powell; J M Rainey; S D Rowley; P Rebulla; M B Troner; A H Wagnon Journal: J Clin Oncol Date: 2001-03-01 Impact factor: 44.544
Authors: Y Bastion; J Y Blay; M Divine; P Brice; D Bordessoule; C Sebban; M Blanc; H Tilly; P Lederlin; E Deconinck; B Salles; C Dumontet; J Brière; B Coiffier Journal: J Clin Oncol Date: 1997-08 Impact factor: 44.544
Authors: K R Meehan; C O Matias; S S Rathore; S G Sandler; J Kallich; J LaBrecque; H Erder; K A Schulman Journal: Am J Hematol Date: 2000-08 Impact factor: 10.047
Authors: D F Cella; D S Tulsky; G Gray; B Sarafian; E Linn; A Bonomi; M Silberman; S B Yellen; P Winicour; J Brannon Journal: J Clin Oncol Date: 1993-03 Impact factor: 44.544
Authors: I Tepler; L Elias; J W Smith; M Hussein; G Rosen; A Y Chang; J O Moore; M S Gordon; B Kuca; K J Beach; J W Loewy; M B Garnick; J A Kaye Journal: Blood Date: 1996-05-01 Impact factor: 22.113
Authors: Thomas M Atkinson; Charissa F Andreotti; Kailey E Roberts; Rebecca M Saracino; Marisol Hernandez; Ethan Basch Journal: Support Care Cancer Date: 2015-08-28 Impact factor: 3.603
Authors: Élodie de Bock; Jean-Benoit Hardouin; Myriam Blanchin; Tanguy Le Neel; Gildas Kubis; Véronique Sébille Journal: Qual Life Res Date: 2014-02-23 Impact factor: 4.147
Authors: Véronique Sébille; Jean-Benoit Hardouin; Tanguy Le Néel; Gildas Kubis; François Boyer; Francis Guillemin; Bruno Falissard Journal: BMC Med Res Methodol Date: 2010-03-25 Impact factor: 4.615
Authors: Jason Tay; David Allan; Sara Beattie; Christopher Bredeson; Dean Fergusson; Dawn Maze; Mitchell Sabloff; Kednapa Thavorn; Alan Tinmouth Journal: BMJ Open Date: 2016-10-24 Impact factor: 2.692
Authors: Abderrahim Khelif; Mansoor N Saleh; Abdulgabar Salama; Maria do Socorro O Portella; Mei Sheng Duh; Jasmina Ivanova; Kelly Grotzinger; Anuja N Roy; James B Bussel Journal: Am J Hematol Date: 2018-11-29 Impact factor: 10.047